Use of 9H-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9H-purine-2,6-diamine derivatives

Details for Australian Patent Application No. 2005230388 (hide)

Owner Novartis AG

Inventors Furet, Pascal; Schoepfer, Joseph; Meier, Peter; Chene, Patrick; Baenteli, Rolf; Collingwood, Stephen Paul

Agent Davies Collison Cave

Pub. Number AU-B-2005230388

PCT Pub. Number WO2005/097135

Priority 0407723.6 05.04.04 GB

Filing date 4 April 2005

Wipo publication date 20 October 2005

Acceptance publication date 17 September 2009

International Classifications

C07D 473/16 (2006.01) Heterocyclic compounds containing purine ring systems

A61K 31/52 (2006.01)

Event Publications

21 September 2006 PCT application entered the National Phase

  PCT publication WO2005/097135 Priority application(s): WO2005/097135

17 September 2009 Application Accepted

  Published as AU-B-2005230388

21 January 2010 Standard Patent Sealed

28 October 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005230392-Thiadiazolidinones as GSK-3 inhibitors

2005230380-Cyclodextrin inclusions complexes of pyrimidine-2,4,6-triones